NGNE
Neurogene Inc.
$37.06
-0.81
(-2.13%)
Mkt Cap
598.43M
Volume
45,473
52W Range
15.93-43.66
Sector
Healthcare
Beta
1.95
EPS (TTM)
-5.51 USD
P/E Ratio
-4.86
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 925,000 | 0 | 0 | 0 | 0 | 0 | 25.00M | 0 | 0 | 0 | 0 |
| Net Income | (90.35M) | (75.14M) | (36.32M) | (55.19M) | (50.52M) | (33.28M) | (69.44M) | (31.59M) | (50.18M) | (37.00M) | (21.86M) | (23.82M) |
| EPS | -4.24 | -4.28 | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 |
| Free Cash Flow | (78.36M) | (71.41M) | (51.74M) | (55.05M) | (64.77M) | (26.79M) | (16.27M) | (31.63M) | (45.21M) | (30.94M) | (20.30M) | (17.92M) |
| FCF / Share | -3.70 | -4.07 | -4.03 | -4.29 | -1.18 | -0.52 | -0.60 | -1.34 | -1.93 | -1.64 | -1.61 | -2.07 |
| Operating CF | (77.17M) | (70.60M) | (51.42M) | (52.82M) | (46.40M) | (24.57M) | (15.39M) | (31.58M) | (44.72M) | (30.23M) | (20.27M) | (17.81M) |
| Total Assets | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M | 210.52M | 147.02M | 77.62M | 110.33M | 154.38M | 113.34M | 41.42M |
| Total Debt | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M | 12.12M | 1.21M | 5,999 | 32,999 | 47,000 | 131,000 | 72,341 |
| Cash & Equiv | 103.84M | 136.59M | 148.21M | 82.02M | 70.54M | 192.56M | 143.09M | 76.93M | 52.03M | 32.30M | 39.53M | 14.91M |
| Book Value | 264.89M | 310.38M | 186.02M | 98.63M | (91.88M) | 191.22M | 141.69M | 72.67M | 98.89M | 144.66M | 108.42M | 36.15M |
| Return on Equity | -0.34 | -0.24 | -0.20 | -0.56 | N/A | -0.17 | -0.49 | -0.43 | -0.51 | -0.26 | -0.20 | -0.66 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 925,000 | 0 | 0 | 0 |
| Net Income | (34.49M) | (30.93M) | (24.73M) | (20.95M) | (22.02M) | (22.65M) | (19.51M) | (20.22M) | (18.49M) | (16.92M) | 2.38M | (14.58M) |
| EPS | -1.53 | -1.39 | -1.60 | -0.99 | -1.05 | -1.08 | -1.31 | -1.19 | -1.09 | -1.00 | -1.21 | -0.41 |
| Free Cash Flow | (24.11M) | (26.40M) | (16.79M) | (19.81M) | (19.61M) | (21.55M) | (17.61M) | (15.73M) | (16.35M) | (21.71M) | (29.28M) | (11.65M) |
| FCF / Share | -1.07 | -1.18 | -1.08 | -0.94 | -0.93 | -1.03 | -1.19 | -0.93 | -0.97 | -1.28 | -2.28 | -1.05 |
| Operating CF | (23.76M) | (26.12M) | (16.67M) | (19.68M) | (19.46M) | (20.77M) | (17.50M) | (15.56M) | (15.89M) | (21.65M) | (29.52M) | (11.57M) |
| Total Assets | 244.36M | 263.14M | 289.18M | 287.83M | 297.32M | 315.30M | 335.73M | 164.12M | 179.82M | 195.35M | 222.57M | 89.59M |
| Total Debt | 8.35M | 9.13M | 9.89M | 11.27M | 12.85M | 13.54M | 12.43M | 14.53M | 13.79M | 14.41M | 16.25M | 11.47M |
| Cash & Equiv | 112.48M | 124.16M | 103.84M | 71.00M | 58.81M | 70.77M | 136.59M | 66.63M | 111.03M | 150.14M | 148.21M | 25.23M |
| Book Value | 217.13M | 237.78M | 264.89M | 265.54M | 273.25M | 291.80M | 310.38M | 137.41M | 155.01M | 170.78M | 186.02M | 75.23M |
| Return on Equity | -0.16 | -0.13 | -0.09 | -0.08 | -0.08 | -0.08 | -0.06 | -0.15 | -0.12 | -0.10 | 0.01 | -0.19 |
NGNE News
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Neurogene Inc. Announces Proposed Public Offering
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome